These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension. Yu C, Geng S, Yang B, Deng Y, Li F, Kang X, Bi M, Zhang F, Zhao Y, Pan W, Tian Z, Xu J, Zhang Z, Yu N, Duan X, Guo S, Sun Q, Li W, Tao J, Liu Z, Yin Y, Wang G. Chin Med J (Engl); 2024 May 20; 137(10):1190-1198. PubMed ID: 38192233 [Abstract] [Full Text] [Related]
25. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis. Poulin Y, Ramon M, Rosoph L, Weisman J, Mendelsohn AM, Parno J, Rozzo SJ, Lee P. J Eur Acad Dermatol Venereol; 2020 Jul 20; 34(7):1500-1509. PubMed ID: 31919889 [Abstract] [Full Text] [Related]
28. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients. Abrouk M, Nakamura M, Zhu TH, Farahnik B, Koo J, Bhutani T. J Dermatolog Treat; 2017 Sep 20; 28(6):488-491. PubMed ID: 28042711 [Abstract] [Full Text] [Related]
29. Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients. Drerup KA, Seemann C, Gerdes S, Mrowietz U. Dermatology; 2022 Sep 20; 238(4):615-619. PubMed ID: 34775387 [Abstract] [Full Text] [Related]